<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302886</url>
  </required_header>
  <id_info>
    <org_study_id>CBHQ880A2204</org_study_id>
    <secondary_id>2010-022029-13</secondary_id>
    <nct_id>NCT01302886</nct_id>
  </id_info>
  <brief_title>Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma</brief_title>
  <official_title>A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the antimyeloma effects of BHQ880A in patients with smoldering&#xD;
      multiple myeloma with high risk of progression to active multiple myeloma. BHQ880 will be&#xD;
      administered every 28 days in previously untreated patients. Disease assessments will be&#xD;
      performed monthly and effects on bone metabolism will be assessed by measurement of serum and&#xD;
      urine bone biomarkers, changes in BMD , and QCT with FEA. Additionally, the PK profile of&#xD;
      BHQ880 as a single agent and following multiple doses will be obtained.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (Complete Response + Partial Response + Minimal Response) of patients achieving an objective response (defined according to the IMWG uniform response criteria by the Frequency of response of serum or urine M-protein to BHQ880A</measure>
    <time_frame>at 6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of BHQ880 in patients with smoldering multiple myeloma by assessing AEs, SAEs, clinical laboratory values</measure>
    <time_frame>From start of study until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the PK profile of BHQ880 as a single agent administered monthly by assessing BHQ880 levels in plasma</measure>
    <time_frame>Throughout the study until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of BHQ880 on bone metabolism by assessing serum and urine bone biomarkers</measure>
    <time_frame>Throughout the study until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of BHQ880 on bone mineral density by DXA scan and QCT</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Smoldering Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>BHQ880</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHQ880</intervention_name>
    <arm_group_label>BHQ880</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of SMM with high-risk for progression to multiple myeloma&#xD;
&#xD;
               1. BMPC ≥ 10% and serum M-protein level ≥ 3 g/dL, OR&#xD;
&#xD;
               2. BMPC ≥ 10%, serum M-protein level &lt; 3 g/dL, and an abnormal free light chain&#xD;
                  ratio of &lt; 0.125 or &gt; 8.0&#xD;
&#xD;
          2. No previous or current anti-myeloma therapies&#xD;
&#xD;
          3. Patients ≥ 18 years of age&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with IV bisphosphonates (i.e., pamidronate or zoledronic acid&#xD;
&#xD;
          2. Another primary malignant disease that requires systemic treatment&#xD;
&#xD;
          3. Concomitant Paget's disease of bone, uncorrected hyperparathyroidism, or uncontrolled&#xD;
             thyroid disease&#xD;
&#xD;
          4. Clinically significant uncontrolled heart disease (e.g., unstable angina, congestive&#xD;
             heart failure, uncontrolled hypertension, ventricular or atrial arrhythmias)&#xD;
&#xD;
          5. Treatment with an investigational product within 28 days before the first dose of&#xD;
             study treatment&#xD;
&#xD;
          6. Pregnant or nursing (lactating) women&#xD;
&#xD;
          7. Women of child-bearing potential, UNLESS they are using two birth control methods. The&#xD;
             two methods can be a double barrier method or a barrier method plus a hormonal method.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group Dept of Highlands Oncology Grp</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute SC - 3</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Indiana Univ</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute DFCI (2)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Dept. of WUSTL</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Multiple Myeloma Division</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine Mt Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center Duke SC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center Fred Hutchinson</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>LILLE Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12765</url>
    <description>Results for CBHQ880A2204 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <disposition_first_submitted>August 20, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 27, 2020</disposition_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High risk Smoldering multiple myeloma,</keyword>
  <keyword>BHQ880,</keyword>
  <keyword>MM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Smoldering Multiple Myeloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

